Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma symptoms

Shihan Chen , Ruyi Lin , Yuhuan Kong , Hao Sun , Jiawen Wang , Jinsong Zhang , Yanshuang Huang , Honghui Wu , Donghang Xu , Jianqing Gao , Tianyuan Zhang

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101122

PDF (5868KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101122 DOI: 10.1016/j.ajps.2026.101122
Research Article
research-article
Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma symptoms
Author information +
History +
PDF (5868KB)

Abstract

Asthma, one of the most prevalent chronic inflammatory diseases, remains challenging to manage effectively. Current therapies commonly alleviate symptoms through broad immunosuppression and bronchodilation but fail to target disease-specific molecular pathways. Genetic intervention using small interfering RNA (siRNA) has emerged as a promising strategy for asthma therapy. However, its success is largely hindered by the lack of an efficient delivery approach targeting airway epithelial cells (AECs). Here, we developed a novel inhalable siRNA delivery system based on artificially prepared nanovesicles through designed extrusion processes of mesenchymal stem cells. To enable an effective inhalation delivery of siRNA via nanovesicles, various parameters, including extrusion cycles, membrane pore sizes, and centrifugal forces were examined through orthogonal testing. Results revealed that the artificially prepared nanovesicles demonstrated remarkable capability to deliver thymic stromal lymphopoietin-targeted siRNA into AECs and substantially suppressed the inflammatory pathways and goblet cell hyperplasia, and eventually achieved a significant inhibition of asthma symptoms in ovalbumin-induced asthma models. Thus, the present study provides a novel nebulized nanovesicle-based carrier for effective delivery of siRNA through local inhalation, offering a promising therapeutic delivery platform for asthma and potentially other respiratory diseases.

Keywords

Nanovesicles / Mesenchymal stem cells / Inhalation / siRNA delivery / Asthma

Cite this article

Download citation ▾
Shihan Chen, Ruyi Lin, Yuhuan Kong, Hao Sun, Jiawen Wang, Jinsong Zhang, Yanshuang Huang, Honghui Wu, Donghang Xu, Jianqing Gao, Tianyuan Zhang. Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma symptoms. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101122 DOI:10.1016/j.ajps.2026.101122

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018; 391(10122): 783-800.

[2]

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1789-858.

[3]

Lommatzsch M, Brusselle GG, Levy ML, Canonica GW, Pavord ID, Schatz M, et al. A2BCD: a concise guide for asthma management. Lancet Respir Med 2023; 11(6): 573-6.

[4]

Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med 2020; 201(3): 276-93.

[5]

Varricchi G, Brightling CE, Grainge C, Lambrecht BN, Chanez P. Airway remodelling in asthma and the epithelium: on the edge of a new era. Eur Respir J 2024; 63(4): 2301619.

[6]

Lu H, Liu X, Zhang M, Bera H, Xu W, Jiang H, et al. Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment. Asian J Pharm Sci 2024; 19(4): 100929.

[7]

You H, Zhang S, Zhang Y, Chen Q, Wu Y, Zhou Z, et al. Engineered bacterial outer membrane vesicles-based doxorubicin and CD47-siRNA co-delivery nanoplatform overcomes immune resistance to potentiate the immunotherapy of glioblastoma. Adv Mater 2025; 37(15): e2418053.

[8]

Keil TWM, Baldassi D, Merkel OM. T-cell targeted pulmonary siRNA delivery for the treatment of asthma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020; 12(5): e1634.

[9]

Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, et al. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma. Eur Respir J 2024; 63(4): 2301397.

[10]

Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets 2020; 24(8): 777-92.

[11]

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther 2024; 32(2): 284-312.

[12]

Witwer KW, Wolfram J. Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat Rev Mater 2021; 6(2): 103-6.

[13]

Khalil IA, Yamada Y, Harashima H. Optimization of siRNA delivery to target sites: issues and future directions. Expert Opin Drug Deliv 2018; 15(11): 1053-65.

[14]

Bai X, Chen Q, Li F, Teng Y, Tang M, Huang J, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat Commun 2024; 15(1): 6844.

[15]

Deng X, Yang Y, Gan L, Duan X, Wang X, Zhang J, et al. Engineering lipid nanoparticles to enhance intracellular delivery of transforming growth factor-beta siRNA (siTGF- β1) via inhalation for improving pulmonary fibrosis post-bleomycin challenge . Pharmaceutics 2025; 17(2): 157.

[16]

Patel AK, Kaczmarek JC, Bose S, Kauffman KJ, Mir F, Heartlein MW, et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv Mater 2019; 31(8): e1805116.

[17]

Sun H, Zhang T, Gao J. Extracellular vesicles derived from mesenchymal stem cells: a potential biodrug for acute respiratory distress syndrome treatment. BioDrugs 2022; 36(6): 701-15.

[18]

Jiang XC, Wu HH, Zhang T, Dong YF, Li YS, Huang T, et al. Biological nano agent produced by hypoxic preconditioning stem cell for stroke treatment. Nano Res 2023; 16(5): 7413-21.

[19]

Han Y, Zhu Y, Youngblood HA, Almuntashiri S, Jones TW, Wang X, et al. Nebulization of extracellular vesicles: a promising small RNA delivery approach for lung diseases. J Control Release 2022; 352: 556-69.

[20]

Fu Z, Zhang X, Zhou X, Ur-Rehman U, Yu M, Liang H, et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. Cell Res 2021; 31(6): 631-48.

[21]

Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol 2024; 19(4): 565-75.

[22]

Zhu D, Liu S, Huang K, Li J, Mei X, Li Z, et al. Intrapericardial long non-coding RNA-Tcf21 antisense RNA inducing demethylation administration promotes cardiac repair. Eur Heart J 2023; 44(19): 1748-60.

[23]

Ding L, Tang S, Wyatt TA, Knoell DL, Oupický D. Pulmonary siRNA delivery for lung disease: review of recent progress and challenges. J Control Release 2021; 330: 977-91.

[24]

Sun D, Mou S, Chen L, Yang J, Wang R, Zhong A, et al. High yield engineered nanovesicles from ADSC with enriched miR-21-5p promote angiogenesis in adipose tissue regeneration. Biomater Res 2022; 26(1): 83.

[25]

Jiang XC, Zhang T, Gao JQ. The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system . Advanced Drug Delivery Reviews 2022; 187: 114324.

[26]

Wang X, Hu S, Li J, Zhu D, Wang Z, Cores J, et al. Extruded mesenchymal stem cell nanovesicles are equally potent to natural extracellular vesicles in cardiac repair. ACS Appl Mater Interfaces 2021; 13(47): 55767-79.

[27]

Wang X, Hu S, Zhu D, Li J, Cheng K, Liu G. Comparison of extruded cell nanovesicles and exosomes in their molecular cargos and regenerative potentials. Nano Res 2023; 16(5): 7248-59.

[28]

Arya SB, Collie SP, Parent CA. The ins-and-outs of exosome biogenesis, secretion, and internalization. Trends Cell Biol 2024; 34(2): 90-108.

[29]

Hirosawa KM, Sato Y, Kasai RS, Yamaguchi E, Komura N, Ando H, et al. Uptake of small extracellular vesicles by recipient cells is facilitated by paracrine adhesion signaling. Nat Commun 2025; 16(1): 2419.

[30]

Kou M, Huang L, Yang J, Chiang Z, Chen S, Liu J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis 2022; 13(7): 580.

[31]

Chen S, Gao J, Zhang T. From mesenchymal stem cells to their extracellular vesicles: progress and prospects for asthma therapy. Asian J Pharm Sci 2024; 19(4): 100942.

[32]

Mu J, Li L, Wu J, Huang T, Zhang Y, Cao J, et al. Hypoxia-stimulated mesenchymal stem cell-derived exosomes loaded by adhesive hydrogel for effective angiogenic treatment of spinal cord injury. Biomater Sci 2022; 10(7): 1803-11.

[33]

Li L, Zhang Y, Mu J, Chen J, Zhang C, Cao H, et al. Transplantation of human mesenchymal stem-cell-derived exosomes immobilized in an adhesive hydrogel for effective treatment of spinal cord Injury. Nano Lett 2020; 20(6): 4298-305.

[34]

Kim HY, Bhang SH. Stem cell-engineered nanovesicles exert proangiogenic and neuroprotective effects. Materials (Basel) 2021; 14(5): 1078.

[35]

Bandeira E, Jang SC, Lässer C, Johansson K, Rådinger M, Park KS. Effects of mesenchymal stem cell-derived nanovesicles in experimental allergic airway inflammation. Respir Res 2023; 24(1): 3.

[36]

Li Z, Cheng Q, Lin L, Fu X, Wang Y. Plasma membrane-derived biomimetic apoptotic nanovesicles targeting inflammation and cartilage degeneration for osteoarthritis. Small Methods 2025; 9(1): e2400660.

[37]

Zelepukin IV, Shevchenko KG, Deyev SM. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. Nat Commun 2024; 15(1): 4366.

[38]

García-Fernández A, Sancenón F, Martínez-Máñez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev 2021; 177: 113953.

[39]

Muskan M, Abeysinghe P, Cecchin R, Branscome H, Morris KV, Kashanchi F. Therapeutic potential of RNA-enriched extracellular vesicles: the next generation in RNA delivery via biogenic nanoparticles. Mol Ther 2024; 32(9): 2939-49.

[40]

Bai X, Zhao G, Chen Q, Li Z, Gao M, Ho W, et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv 2022; 8(25): eabn7162.

[41]

Lai JJ, Chau ZL, Chen SY, Hill JJ, Korpany KV, Liang NW, et al. Exosome processing and characterization approaches for research and technology development. Adv Sci (Weinh) 2022; 9(15): e2103222.

[42]

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-17.

[43]

Miller RL, Grayson MH, Strothman K. Advances in asthma: new understandings of asthma’s natural history, risk factors, underlying mechanisms, and clinical management. J Allergy Clin Immunol 2021; 148(6): 1430-41.

[44]

Liu Q, Guan J, Qin L, Zhang X, Mao S. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discov Today 2020; 25(1): 150-9.

[45]

He Y, Liang Y, Han R, Lu WL, Mak JCW, Zheng Y. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy. J Control Release 2019; 314: 48-61.

[46]

Liu Q, Guan J, Song R, Zhang X, Mao S. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants. Acta Biomater 2022; 140: 76-87.

[47]

Mirershadi F, Ahmadi M, Rezabakhsh A, Rajabi H, Rahbarghazi R, Keyhanmanesh R. Unraveling the therapeutic effects of mesenchymal stem cells in asthma. Stem Cell Res Ther 2020; 11(1): 400.

[48]

Hong H, Liao S, Chen F, Yang Q, Wang DY. Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation. Allergy 2020; 75(11): 2794-804.

[49]

Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, et al. Eosinophils and tissue remodeling: relevance to airway disease. J Allergy Clin Immunol 2023; 152(4): 841-57.

[50]

Du X, Li F, Zhang C, Li N, Huang H, Shao Z, et al. Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation. Signal Transduct Target Ther 2021; 6(1): 91.

[51]

Chen S, Chen G, Xu F, Sun B, Chen X, Hu W, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov 2022; 8(1): 80.

[52]

Huang S, Li Y, Zeng J, Chang N, Cheng Y, Zhen X, et al. Mesenchymal Stem/stromal cells in asthma therapy: mechanisms and strategies for enhancement. Cell Transplant 2023; 32: 9636897231180128.

[53]

Kumar S, Corkran M, Cheema Y, Scull MA, Duncan GA. AAV-mediated MUC5AC siRNA delivery to prevent mucociliary dysfunction in asthma. Gene Ther 2025; 32(5): 508-16.

[54]

Ahmadian S, Jafari N, Tamadon A, Ghaffarzadeh A, Rahbarghazi R, Mahdipour M. Different storage and freezing protocols for extracellular vesicles: a systematic review. Stem Cell Res Ther 2024; 15(1): 453.

[55]

Rezabakhsh A, Sokullu E, Rahbarghazi R. Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine. Stem Cell Res Ther 2021; 12(1): 521.

[56]

Yuan F, Li YM, Wang Z. Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation. Drug Deliv 2021; 28(1): 1501-9.

[57]

Levy D, Jeyaram A, Born LJ, Chang KH, Abadchi SN, Hsu ATW, et al. Impact of storage conditions and duration on function of native and cargo-loaded mesenchymal stromal cell extracellular vesicles. Cytotherapy 2023; 25(5): 502-9.

[58]

Susa F, Limongi T, Borgione F, Peiretti S, Vallino M, Cauda V, et al. Comparative studies of different preservation methods and relative freeze-drying formulations for extracellular vesicle pharmaceutical applications. ACS Biomater Sci Eng 2023; 9(10): 5871-85.

[59]

Mišík O, Kejíková J, Cejpek O, Malý M, Jugl A, Bˇelka M, et al. Nebulization and in vitro upper airway deposition of liposomal carrier systems . Mol Pharm 2024; 21(4): 1848-60.

PDF (5868KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉